Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world enzalutamide + ADT in metastatic hormone-sensitive prostate cancer
ChiCTR2500109370Phase 4Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Prostate specific antigen. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500109370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109370.